¼¼°èÀÇ mRNA ¹é½Å ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)
Global mRNA Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
»óǰÄÚµå : 1481828
¸®¼­Ä¡»ç : Value Market Research
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 126 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,920 £Ü 5,671,000
PDF & Excel (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÀüÀÚÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,730 £Ü 6,843,000
PDF & Excel (10-user License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» 10¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÀüÀÚÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,430 £Ü 10,750,000
PDF & Excel (Corporate User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÀüÀÚÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

mRNA ¹é½ÅÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 222¾ï 3,000¸¸ ´Þ·¯¿¡¼­ 2032³â 137¾ï 3,000¸¸ ´Þ·¯¿¡ À°¹ÚÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2024-2033³â ¿¬Æò±Õ -5.21%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

mRNA ¹é½ÅÀº ¸Þ½ÅÀú RNA(mRNA) ºÐÀÚ¸¦ »ç¿ëÇÏ¿© ü³» ¼¼Æ÷°¡ ¹ÙÀÌ·¯½º³ª ¹ÚÅ׸®¾Æ¿Í °°Àº ƯÁ¤ º´¿ø±Õ¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁúÀ» ¸¸µéµµ·Ï ÇÕ´Ï´Ù. ÀÌ ¹é½ÅÀº ¹ÙÀÌ·¯½º³ª ¹ÚÅ׸®¾ÆÀÇ Ç׿øÀ» ¾ÏȣȭÇÏ´Â ÇÕ¼º mRNA ¼­¿­À» ¼¼Æ÷·Î º¸³» ¸é¿ª ¹ÝÀÀÀ» À¯¹ßÇÏ´Â ´Ü¹éÁú Ç׿øÀ¸·Î ¹ø¿ªÇÕ´Ï´Ù. ÀÌ ¹é½ÅÀº »ì¾ÆÀÖ´Â º´¿øÃ¼¸¦ Æ÷ÇÔÇÏÁö ¾Ê±â ¶§¹®¿¡ ±âÁ¸ ¹é½Åº¸´Ù ¾ÈÀüÇϸç, ½ÅÁ¾ °¨¿°º´¿¡ ´ëÀÀÇØ ½Å¼ÓÇÏ°Ô °³¹ß ¹× »ý»êÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ¹é½ÅµéÀº COVID-19¿Í °°Àº °¨¿°º´ ¿¹¹æÀ» À§ÇÑ ÀÓ»ó½ÃÇè¿¡¼­ À¯¸ÁÇÑ °á°ú¸¦ º¸¿´À¸¸ç, ¾Ï ¹× ±âŸ Áúº´ Ä¡·á¿¡µµ Àû¿ë °¡´É¼ºÀ» °ËÅäÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

COVID-19 ÆÒµ¥¹Í¿¡ ´ëÀÀÇϱâ À§ÇÑ ±ä±ÞÇÑ Çʿ伺À¸·Î ÀÎÇØ ¹ÙÀÌ·¯½º °¨¿°À» ¿¹¹æÇϱâ À§ÇÑ À¯¸ÁÇÑ Á¢±Ù¹ýÀ¸·Î mRNA ¹é½ÅÀÇ ¿¬±¸, °³¹ß ¹× ¹èÆ÷°¡ °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, Pfizer-BioNTech ¹é½Å ¹× Moderna COVID-19 ¹é½Å°ú °°Àº mRNA ¹é½Å Àº ÀÓ»ó½ÃÇè°ú ½ÇÁ¦ ÀÓ»ó½ÃÇè¿¡¼­ ³ôÀº È¿´ÉÀ» º¸¿© SARS-CoV-2 °¨¿°°ú ½É°¢ÇÑ COVID-19 Áúȯ¿¡ ´ëÇÑ ½Å¼ÓÇÑ ¹æ¾î·ÂÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ¹é½ÅÀº ±âÁ¸ ¹é½Å ±â¼ú¿¡ ºñÇØ °³¹ß ±â°£ ´ÜÃà, È®À强, ¿ì·ÁµÇ´Â »õ·Î¿î º¯Á¾¿¡ ´ëÇÑ ÀûÀÀ¼º µî ¸î °¡Áö ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19¿¡ ´ëÇÑ ¼º°øÀûÀÎ ´ëÀÀÀº µ¶°¨, HIV, ÁöÄ« ¹ÙÀÌ·¯½º, È£Èí±â¼¼Æ÷À¶ÇÕ¹ÙÀÌ·¯½º(RSV) µî ´Ù¾çÇÑ °¨¿°¼º Áúȯ¿¡ ´ëÇÑ °ü½É°ú ÅõÀÚ¸¦ ºÒ·¯ÀÏÀ¸Ä×½À´Ï´Ù. ¶ÇÇÑ, mRNA ¹é½ÅÀº ¸é¿ªÃ¼°è°¡ Á¾¾ç ¼¼Æ÷¸¦ ÀνÄÇϰí Ç¥ÀûÀ¸·Î »ï´Â °ÍÀ» ÃËÁøÇÏ¿© °³ÀÎ ¸ÂÃãÇü ¾Ï Ä¡·á¿¡ ´ëÇÑ À¯¸ÁÇÑ Á¢±Ù¹ýÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ¾Ï ¸é¿ª¿ä¹ý¿¡µµ Àû¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦Á¶ ÆÄÆ®³Ê½Ê, ±â¼úÀÌÀü °è¾à, »ý»ê´É·Â È®´ë ÀÌ´Ï¼ÅÆ¼ºêÀÇ ÃâÇöÀ¸·Î ÀÎÇØ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ°í °ø±Þ¸Á ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ÀÌ·¯ÇÑ ¹é½ÅÀÇ ¼¼°è »ý»ê ¹× À¯ÅëÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ´ëü ¹é½Å ±â¼úÀÇ ÃâÇö°ú Àå±âÀûÀÎ À¯È¿¼º ¹× ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á´Â ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀå ¼ºÀå¿¡ µµÀüÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â »ê¾÷ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â mRNA ¹é½Å ¼¼°è ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Æ÷°ýÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖÀ¸¸ç, mRNA ¹é½Å »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ Àü¹ÝÀûÀÎ Á¢±Ù ¹æ½ÄÀ» ¼³¸íÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

mRNA ¹é½Å ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡µéÀÌ ÇâÈÄ ±âȸ¸¦ ÅëÇØ °¢ Á¦Ç° ¹× ¼­ºñ½ºÀÇ ´ë»ó °í°´À» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

¿ëµµº°

ÃÖÁ¾»ç¿ëÀÚº°

Áö¿ªº° ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ mRNA ¹é½Å ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ÀÀ¿ë ºÐ¾ß¿¡ ´ëÇÑ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ¿ä±¸»çÇ×ÀÌ ÀÖ´Â °æ¿ì, ÀúÈñ¿¡°Ô ¿¬¶ôÁֽñ⠹ٶø´Ï´Ù. ´ç»çÀÇ Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå mRNA ¹é½Å - »ê¾÷ ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦5Àå mRNA ¹é½Å ¼¼°è ½ÃÀå ºÐ¼® : ¿ëµµº°

Á¦6Àå mRNA ¹é½Å ¼¼°è ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦7Àå mRNA ¹é½Å ¼¼°è ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦8Àå mRNA ¹é½Å ±â¾÷ °æÀï »óȲ

Á¦9Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global demand for mRNA Vaccine Market is presumed to reach the market size of nearly USD 13.73 Billion by 2032 from USD 22.23 Billion in 2023 with a CAGR of -5.21% under the study period 2024-2033.

mRNA vaccines use messenger RNA (mRNA) molecules to instruct cells in the body to make proteins that stimulate an immune response against specific pathogens, such as viruses or bacteria. These vaccines deliver synthetic mRNA sequences encoding viral or bacterial antigens into cells, translating them into protein antigens that trigger an immune response. They do not contain live pathogens, making them safer than traditional vaccines, and they can be rapidly developed and produced in response to emerging infectious diseases. These vaccines have demonstrated promising results in clinical trials for preventing infectious diseases such as COVID-19 and are being investigated for their potential applications in treating cancer and other diseases.

MARKET DYNAMICS

The urgent need to tackle the COVID-19 pandemic has accelerated the research, development, and deployment of mRNA vaccines as a promising approach to preventing viral infections. mRNA vaccines, such as the Pfizer-BioNTech and Moderna COVID-19 vaccines, have resulted in high efficacy in clinical trials and real-world studies, offering rapid protection against SARS-CoV-2 infection and severe COVID-19 disease. Additionally, these vaccines provide several advantages over traditional vaccine technologies, including faster development timelines, scalability, and adaptability to emerging variants of concern. Moreover, the success in addressing the COVID-19 pandemic has sparked interest and investment in various infectious diseases, including influenza, HIV, Zika virus, and respiratory syncytial virus (RSV). Furthermore, the potential applications of these vaccines extend beyond infectious diseases to include cancer immunotherapy, where mRNA vaccines can accelerate the immune system to recognize and target tumor cells, offering a promising approach to personalized cancer treatment. Additionally, the emergence of manufacturing partnerships, technology transfer agreements, and capacity expansion initiatives is accelerating global production and distribution of these vaccines to meet growing demand and address supply chain challenges. However, the emergence of alternative vaccine technologies and concerns about long-term efficacy and safety may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of mRNA Vaccine. The growth and trends of mRNA Vaccine industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the mRNA Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

By End-user

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the mRNA Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the mRNA Vaccine market include Pfizer Inc., Moderna Inc., Novartis AG, Sanofi, Arcturus, Gennova Biopharmaceuticals Ltd., Aimei Vaccine Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. MRNA VACCINE - INDUSTRY ANALYSIS

4. VALUE CHAIN ANALYSIS

5. GLOBAL MRNA VACCINE MARKET ANALYSIS BY APPLICATION

6. GLOBAL MRNA VACCINE MARKET ANALYSIS BY END-USER

7. GLOBAL MRNA VACCINE MARKET ANALYSIS BY GEOGRAPHY

8. COMPETITIVE LANDSCAPE OF THE MRNA VACCINE COMPANIES

9. COMPANY PROFILES OF MRNA VACCINE INDUSTRY

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â